Compare · NMRA vs VNDA
NMRA vs VNDA
Side-by-side comparison of Neumora Therapeutics Inc. (NMRA) and Vanda Pharmaceuticals Inc. (VNDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. NMRA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while VNDA focuses on Biotechnology: Pharmaceutical Preparations.
- VNDA is the larger of the two at $230.4M, about 3.7x NMRA ($61.9M).
- VNDA has been more active in the news (9 items in the past 4 weeks vs 5 for NMRA).
- NMRA has more recent analyst coverage (23 ratings vs 6 for VNDA).
- Company
- Neumora Therapeutics Inc.
- Vanda Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $61.9M
- $230.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2006
- News (4w)
- 5
- 9
- Recent ratings
- 23
- 6
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Latest NMRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Neumora Therapeutics Inc.
- SEC Form 10-Q filed by Neumora Therapeutics Inc.
- Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Neumora Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)
- SEC Form 4 filed by Officer Berns Paul L
- SEC Form 4 filed by Officer Duncan Jason
- SEC Form 4 filed by Officer Milligan Michael Lee
- SEC Form 4 filed by President & CEO Pinto Joshua
Latest VNDA
- Amendment: SEC Form SCHEDULE 13G/A filed by Vanda Pharmaceuticals Inc.
- NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
- SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.
- Director Duncan Charles Cliff bought $38,094 worth of shares (10,000 units at $3.81), increasing direct ownership by 10% to 108,701 units (SEC Form 4)
- Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
- SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.
- SEC Form 8-K filed by Vanda Pharmaceuticals Inc.
- Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
- Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026